

BRIEF REPORT

FTO, Type 2 Diabetes, and Weight Gain Throughout Adult Life

A Meta-Analysis of 41,504 Subjects From the Scandinavian HUNT, MDC, and MPP Studies

Jens K. Hertel,^{1,2} Stefan Johansson,^{1,2} Emily Sonestedt,^{3,4} Anna Jonsson,⁵ Rolv T. Lie,⁶ Carl G.P. Platou,^{7,8} Peter M. Nilsson,⁹ Gull Rukh,⁴ Kristian Midthjell,⁷ Kristian Hveem,⁷ Olle Melander,¹⁰ Leif Groop,^{5,11} Valeriya Lyssenko,⁵ Anders Molven,^{12,13} Marju Orho-Melander,⁴ and Pål R. Njølstad^{1,14}

OBJECTIVE—*FTO* is the most important polygene identified for obesity. We aimed to investigate whether a variant in *FTO* affects type 2 diabetes risk entirely through its effect on BMI and how *FTO* influences BMI across adult life span.

RESEARCH DESIGN AND METHODS—Through regression models, we assessed the relationship between the *FTO* single nucleotide polymorphisms rs9939609, type 2 diabetes, and BMI across life span in subjects from the Norwegian population-based HUNT study using cross-sectional and longitudinal perspectives. For replication and meta-analysis, we used data from the Malmö Diet and Cancer (MDC) and Malmö Preventive Project (MPP) cohorts, comprising a total sample of 41,504 Scandinavians.

RESULTS—The meta-analysis revealed a highly significant association for rs9939609 with both type 2 diabetes (OR 1.13; $P = 4.5 \times 10^{-8}$) and the risk to develop incident type 2 diabetes (OR 1.16; $P = 3.2 \times 10^{-8}$). The associations remained also after correction for BMI and other anthropometric measures. Furthermore, we confirmed the strong effect on BMI (0.28 kg/m² per risk allele; $P = 2.0 \times 10^{-26}$), with no heterogeneity between different age-groups. We found no differences in change of BMI over time according to rs9939609 risk alleles, neither overall (Δ BMI = 0.0

[−0.05, 0.05]) nor in any individual age stratum, indicating no further weight gain attributable to *FTO* genotype in adults.

CONCLUSIONS—We have identified that a variant in *FTO* alters type 2 diabetes risk partly independent of its observed effect on BMI. The additional weight gain as a result of the *FTO* risk variant seems to occur before adulthood, and the BMI difference remains stable thereafter. *Diabetes* 60:1637–1644, 2011

Genomewide association studies (GWAS) have identified a strong correlation between BMI and *FTO* single nucleotide polymorphisms (SNPs) (1–4), and the association has been confirmed in multiple populations (reviewed in 5). The *FTO* risk variants are also associated with obesity-related traits (6–8). However, these effects appear to be secondary to weight increase because the associations are attenuated after adjusting for BMI (2). In contrast, we and others have found that the association with type 2 diabetes may not be completely mediated through BMI, because it remains significant after BMI correction (9). This indicates that the relationship between sequence variation in *FTO* and type 2 diabetes is not fully mediated through BMI or that BMI in some populations does not reveal accurate estimates of the effect of *FTO* on adiposity.

Various studies have investigated the effect of *FTO* variants on BMI and weight in a longitudinal perspective (10–18) but with diverging results. With access to extensive data from three large Scandinavian populations, through a meta-analysis approach using both cross-sectional and longitudinal data, we aimed to investigate whether the *FTO* risk allele affects type 2 diabetes risk after correction for BMI and whether it influences weight gain during adult life.

RESEARCH DESIGN AND METHODS

Definition of cohorts. We studied HUNT2, a subset (aged ≥ 20) of a Norwegian population-based health survey (Nord-Trøndelag Health Study) (19). Our material comprised 1,740 diabetic individuals (1,543 with type 2 diabetes) and 3,856 population-based control subjects drawn from the same study population. We also had access to data on diabetes status, weight, and height from HUNT1 (1985) for 4,625 of the 5,596 subjects in HUNT2 (1995), i.e., 10-year follow-up. During these 10 years, 1,089 individuals developed type 2 diabetes. Diagnosis of diabetes was self-reported or identified by standard tests if random glucose was >8.0 mmol/L.

The Malmö Diet and Cancer (MDC) cohort (20) with baseline examinations from 1991 to 1996 consisted of 28,449 individuals. All men born between 1923 and 1945 and all women born between 1923 and 1950 from Malmö were

From the ¹Department of Clinical Medicine, University of Bergen, Bergen, Norway; the ²Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway; the ³Department of Clinical Sciences in Malmö, Nutrition Epidemiology, Lund University, Malmö, Sweden; the ⁴Department of Clinical Sciences in Malmö, Diabetes and Cardiovascular Disease-Genetic Epidemiology, Lund University, Malmö, Sweden; the ⁵Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, and Lund University Diabetes Centre, Malmö, Sweden; the ⁶Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway; the ⁷HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Verdal, Norway; the ⁸Department of Internal Medicine, Levanger Hospital, Nord-Trøndelag Health Trust, Norway; the ⁹Department of Clinical Sciences, Division of Medicine, Lund University, Malmö, Sweden; the ¹⁰Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, University Hospital Malmö, Lund University, Malmö, Sweden; the ¹¹Department of Medicine, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; the ¹²Gade Institute, University of Bergen, Bergen, Norway; the ¹³Department of Pathology, Haukeland University Hospital, Bergen, Norway; and the ¹⁴Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.

Corresponding author: Pål R. Njølstad, pal.njolstad@uib.no.

Received 20 September 2010 and accepted 17 February 2011.

DOI: 10.2337/db10-1340

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1340/-DC1>.

J.K.H. and S.J. contributed equally to this work.

E.S. and A.J. contributed equally to this work.

© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

invited. Diabetes diagnosis at baseline was self-reported or diagnosed if fasting plasma glucose was ≥ 7.0 mmol/L.

In the Malmö Preventive Project (MPP) cohort (21), 33,346 subjects from Malmö participated in a health screening. Men were included from 1974 to 1990, and women were included from 1980 to 1992. Eligible participants (25,000) were invited to a rescreening visit during 2002–2006. Of those invited, 16,061 nondiabetic subjects, 2,063 of whom developed type 2 diabetes during follow-up, were included in the current study. Diabetes diagnosis was taken from patient records or if fasting plasma glucose was ≥ 7.0 mmol/L.

The clinical characteristics of individuals from the three cohorts are shown in Table 1.

SNP selection, genotyping, and quality control. Because the reported obesity-associated *FTO* SNPs are in strong to perfect linkage disequilibrium (LD) (pairwise $r^2 > 0.8$; HapMap; CEU, release 21), we included rs9939609, reported by the first GWAS (2), as proxy. We genotyped HUNT2 subjects by MassARRAY *iPLEX* System (SEQUENOM, San Diego, CA). Duplicate concordance rate was 99.7% ($N = 3,761$). MDC individuals were genotyped using MassARRAY *iPLEX* System or a TaqMan assay (Applied Biosystems, Foster City, CA). Individuals (249 total) were genotyped with both methods (99.4% allelic concordance rate). A total of 8,175 individuals were genotyped twice (allelic concordance rate 99.3%). MPP subjects were genotyped by TaqMan assay with duplicate concordance rate 99.7% ($N = 7,926$). The final genotyping success rates were 99.7, 99.2, and 97.2%, in HUNT2, MPP, and MDC, respectively. The *FTO* SNP was in Hardy-Weinberg equilibrium (P value > 0.05) in all cohorts.

Statistical analysis. We used logistic regression to investigate the association between type 2 diabetes and *FTO* genotype under an additive model. Age, sex, different combinations of BMI, waist circumference, and waist-to-hip ratio were included as covariates. In HUNT2 and MPP, follow-up measures were used unless otherwise stated. In MDC, baseline measures were used because of no available follow-up. To evaluate the risk of developing incident type 2 diabetes according to the three *FTO* genotypic classes, we designed a case-control study using only subjects who were healthy at baseline. Those developing type 2 diabetes during follow-up were defined as cases and the rest as control subjects. We used logistic regression models corrected for sex, baseline age, and BMI. In a second step, we included the change in BMI over time (Δ BMI) as an additional cofactor.

To analyze the association between *FTO* genotype and BMI, we used linear regression models assuming additive effects of allele dosage with adjustment for age, sex, and diabetes status. Logarithmic transformation of BMI values did not change the results; thus, only results using nontransformed BMI are presented. To assess whether the allele-wise increase in BMI differed across different adult ages, we performed individual analysis in every 10-year age stratum in the cross-sectional and longitudinal datasets. Finally, meta-analysis was performed to combine the regression coefficients (per allele change in BMI) with their standard errors from within the three cohorts and for each specific age-group. Interstudy heterogeneity and heterogeneity between different age-groups were estimated using Cochran's Q test and the I^2 statistic. Overall estimates were calculated using a fixed-effect model with inverse variance.

We performed statistical analyses by PLINK (22) and Stata SE v10.0 (Stata, Brownsville, TX) or SPSS (version 18; SPSS Inc., Chicago, IL). Meta-analysis statistics and plots were produced using the METAN module (23) developed for Stata and with GWAMA (Genome-Wide Association Meta-Analysis) software (24).

RESULTS

Relationship among *FTO*, type 2 diabetes, and obesity-related quantitative traits across life span in HUNT. After correction for age and sex, we observed a strong association with type 2 diabetes for rs9939609 in HUNT2. This association remained significant after correction for BMI (OR 1.19 [95%CI 1.09–1.30]; $P = 1.8 \times 10^{-5}$). The *FTO* variant also conferred an increased risk for type 2 diabetes after adjustment for waist circumference and waist-to-hip ratio. These results suggested that rs9939609 has an effect on the risk of type 2 diabetes, an effect that cannot be entirely explained through increased BMI or central obesity.

Using a cross-sectional design, we observed that the *FTO*-associated allele-wise increase in BMI persisted at the same level throughout life (Supplementary Fig. 1). In addition, rs9939609 \times age interactions on obesity-related traits were all nonsignificant (Supplementary Table 1), suggesting that changes in these traits by age were not dependent on the individual's *FTO* genotype.

Next, we studied longitudinal change in the association between *FTO* and BMI during 10-year follow-up from HUNT1 to HUNT2. The *FTO* variant showed an association with all obesity-related quantitative traits (Supplementary Table 1). There was, however, no association between rs9939609 and Δ BMI between 1985 and 1995. This suggested that the *FTO*-associated relative difference of BMI is established before adulthood and then remains stable.

Confirmation of the findings from HUNT–meta-analysis in 41,504 Scandinavians. Clinical characteristics of individuals from the three different cohorts are presented in Table 1. The minor allele frequencies of rs9939609 in nondiabetic individuals were 0.42, 0.41, and 0.41 in HUNT2, MPP, and MDC, respectively.

The meta-analysis demonstrated that the association between rs9939609 and type 2 diabetes was strong after adjustment for age and sex (OR 1.13 [95%CI 1.08–1.19]; $P = 4.5 \times 10^{-8}$) and remained significant after BMI correction (OR 1.09 [95%CI 1.04–1.15]; $P = 1.2 \times 10^{-4}$; Fig. 1A and B). Correction for waist-to-hip ratio or waist circumference instead of BMI did not change the results (Supplementary Fig. 2A–C). To further elucidate whether rs9939609 exerts an effect on type 2 diabetes independently of BMI, we evaluated the risk to develop incident type 2 diabetes according to *FTO* genotype during follow-up. As shown in Supplementary Fig. 3A–C, the association remained similar for incident type 2 diabetes after correction for sex and baseline age and BMI (OR 1.12 [95%CI 1.05–1.18]; $P = 1.1 \times 10^{-4}$) and after correction also for Δ BMI (OR 1.11 [95%CI 1.05–1.18]; $P = 1.5 \times 10^{-4}$).

The meta-analysis of the *FTO*-associated allele-wise effect on BMI using cross-sectional data confirmed the strong effect of the *FTO* SNP on BMI (0.28 kg/m² per risk allele [$P = 2.0 \times 10^{-26}$]; Fig. 2A). Furthermore, we detected no heterogeneity in the effect sizes for the *FTO* risk allele between the different age-groups (Fig. 2B). Finally, Fig. 3 shows the linear regression summary results between rs9939609 and Δ BMI for all HUNT and MPP individuals for whom longitudinal data were available. There was no significant difference in Δ BMI according to overall number of rs9939609 risk alleles (Δ BMI = 0.0 [−0.05, 0.05]) or in any individual age stratum (Fig. 3B). Hence, the *FTO*-associated effect on BMI seems to establish relatively early in life, and the relative BMI difference remains stable across adult life.

DISCUSSION

To our knowledge, this is the largest study investigating the effect of *FTO* sequence variants on type 2 diabetes and BMI across the whole range of adult ages and in a longitudinal perspective. In 41,504 Scandinavians, we demonstrate that a common variant of *FTO* does not mediate type 2 diabetes risk entirely through its influence on BMI. Although our findings are comparable with some earlier studies (25–27), they contrast previous results reported in most populations studied to date, including Europeans (1–3,8). Reasons for the diverging results could be differences in selection or recruitment of cases and control subjects between studies, differences in undetected key effects at early age, or population-specific environmental factors that may interact with the way *FTO* works to influence the risk of type 2 diabetes. In an attempt to capture the complex relationship between *FTO*, BMI, and type 2 diabetes during the life course, we performed an analysis on incident type 2 diabetes. The results remained similar in the longitudinal

TABLE 1
Clinical characteristics of the individuals from the three different cohorts

	HUNT				MPP				MDC			
	N	All	N	Type 2 diabetes	N	No type 2 diabetes	N	All	N	Type 2 diabetes	N	Type 2 diabetes
Individuals (n)	5,596	—	1,543	—	4,053	—	15,980	—	2,054	—	13,876	—
Sex (male/female)	5,596	2,788/2,808	1,543	726/817	4,053	2,062/1,991	15,980	10,335/5,595	2,054	1,604/450	13,876	8,731/5,145
Age (years)	5,596	59.8 ± 17.1	1,543	67.9 ± 12.0	4,053	56.7 ± 17.8	15,980	45.5 ± 6.9	2,054	45.0 ± 6.3	13,876	45.6 ± 7.0
Follow-up time (years)	4,625	10	1,421	10	3,204	10	15,980	23.5 ± 4.2	2,054	24.5 ± 3.4	13,876	23.4 ± 4.3
BMI baseline (kg/m ²)	4,625	26.8 ± 4.4	1,421	29.5 ± 4.8	3,204	25.6 ± 3.7	15,925	24.3 ± 3.3	2,054	26.2 ± 3.8	13,871	24.0 ± 3.1
BMI (kg/m ²)	5,596	27.3 ± 4.6	1,543	29.3 ± 4.8	4,053	26.6 ± 4.1	15,843	27.1 ± 4.1	2,038	29.3 ± 4.6	13,805	26.8 ± 3.9
Waist-to-hip ratio	5,552	0.86 ± 0.1	1,530	0.89 ± 0.1	4,022	0.86 ± 0.1	15,820	0.92 ± 0.1	2,030	0.97 ± 0.1	13,790	0.91 ± 0.1
Waist circumference (cm)	5,552	90.3 ± 12.2	1,530	95.8 ± 11.8	4,022	88.2 ± 11.6	15,829	94.8 ± 12.2	2,030	102.1 ± 12.1	13,789	98.7 ± 11.8
Serum triglycerides (mmol/L)	5,583	2.0 ± 1.3	1,534	2.5 ± 1.6	4,049	1.8 ± 1.1	15,921	1.3 ± 0.8	2,052	1.6 ± 1.2	13,869	1.2 ± 0.7
Serum cholesterol (mmol/L)	5,584	6.1 ± 1.3	1,534	6.2 ± 1.3	4,050	6.1 ± 1.3	15,923	5.6 ± 1.1	2,052	5.2 ± 1.1	13,871	5.7 ± 1.1
Serum HDL (mmol/L)	5,582	1.3 ± 0.4	1,533	1.2 ± 0.4	4,049	1.4 ± 0.4	15,915	1.4 ± 0.4	2,052	1.2 ± 0.4	13,863	1.4 ± 0.4
Fasting plasma glucose (mmol/L)*	5,582	6.8 ± 3.3	1,533	9.6 ± 4.2	4,049	5.7 ± 1.9	15,921	5.8 ± 1.3	2,050	7.9 ± 2.4	13,871	5.5 ± 0.5

Data are presented as means ± SD. Data presented for the HUNT and MPP cohorts are follow-up measures unless otherwise stated. All data presented for the MDC cohort are baseline measures as a result of no available follow-up measures. *Only nonfasting glucose measures were available for participants in the HUNT cohort.



A**B**

FIG. 1. Meta-analysis plots of association between *FTO* and type 2 diabetes comprising 4,317 subjects with type 2 diabetes and 37,187 control subjects. **A:** Meta-analysis plot of association between *FTO* rs9939609 and type 2 diabetes after correction for age and sex (allelic OR 1.13 [95% CI 1.08–1.19]). **B:** Meta-analysis plot of association between *FTO* rs9939609 and type 2 diabetes after correction for age, sex, and BMI (allelic OR 1.09 [1.04–1.15]). We observed a tendency toward heterogeneity between the samples ($P = 0.064$), and the variation in the estimate attributable to heterogeneity was calculated to 63.7%. The ORs for the overall estimates were calculated using a fixed-effect model with inverse variance. The weighting (%weight) represents the inverse variance of each studies' effect estimator.

study both when we controlled for BMI at baseline (before diabetes was diagnosed), Δ BMI, or waist circumference and/or waist-to-hip ratio as covariates in the regression analyses. None of the covariates alone or in combination with BMI changed our results notably. *FTO* still conferred an increased risk for type 2 diabetes.

How sequence variation in *FTO* could possibly affect type 2 diabetes risk in other forms than through increased adiposity remains elusive. No associations have been reported between *FTO* SNPs and glucose tolerance or insulin sensitivity. A link between SNPs in *FTO* and altered lipid profiles has been suggested (6,9), but we could not confirm this in our meta-analysis (Supplementary Table 2). It has been suggested that rs9939609 affects the primary allelic *FTO* transcript levels (28), and correlations have been observed in peripheral tissues between BMI of tissue donors and *FTO* mRNA expression levels (29). It is

noteworthy that three recent *FTO* expression studies support a potential role in type 2 diabetes independently of BMI. One study found no association between *FTO* expression and BMI in islet cells (30). Another study reported an inverse correlation between *Fto* mRNA and glucose in mice after correction for body weight (31). Finally, a third study found an increase of *FTO* mRNA and protein levels in muscle from type 2 diabetic patients compared with healthy lean control subjects or BMI-matched obese non-diabetic individuals (32). The latter also suggests that increased *FTO* expression in type 2 diabetic patients contributes to reduced mitochondria oxidative capacities, lipid accumulation, and oxidative stress, all associated with type 2 diabetes. It is also possible that the rs9939609 SNP (or a SNP in strong LD) affects another gene in the region, which has the potential to alter type 2 diabetes risk independently of BMI (33).




FIG. 2. Meta-analysis plot of the *FTO*-associated allele-wise effect on BMI using cross-sectional data. The results included in the meta-analysis are from regression analysis adjusted for age, sex, and diabetes status. The weighting (%weight) represents the inverse variance of each study's effect estimator. **A:** Meta-analysis plot comprising all 41,504 individuals. No heterogeneity between the cohorts was detected ($P = 0.242$), and the overall allelic effect was estimated to 0.28 kg/m². **B:** Meta-analysis plot comprising all 41,504 individuals stratified on 10-year age strata. No heterogeneity between the subgroups was detected ($P = 0.378$). Moderate heterogeneity was, however, observed in two of the subgroups.

The association between *FTO* sequence variants and BMI is not established at birth (2,34) but seems to evolve gradually before adulthood (2,35,36). It is not clear how *FTO* genotype affects BMI after adolescence and develops during the life course (10–18), although a recent longitudinal Finnish study suggests that the effect may continue into adulthood since they found an association between rs9939609 and BMI at age 31, which could not be explained

by the BMI at age 14 (18). Using cross-sectional and longitudinal designs, we identified in the three Scandinavian populations that the relative difference in mean BMI among individuals with different rs9939609 genotypes remains surprisingly stable across all adult ages. Hence, because our study primarily comprised individuals that were above 30 years of age (98.7%), current evidence suggest that the *FTO* variant increases BMI in the first 2 to 3 decades of life,




FIG. 3. Meta-analysis plot of the *FTO*-associated effect on BMI differences using longitudinal data from the HUNT and MPP study. The results included in the meta-analysis are from regression analysis adjusted for age, sex, and diabetes status. The weighting (%weight) represents the inverse variance of each study's effect estimator. **A:** Meta-analysis plot comprising all 20,464 individuals with follow-up data on BMI. No heterogeneity between the cohorts was detected ($P = 0.892$), and the overall allelic effect for the *FTO* SNP on BMI difference over a period of time was estimated to 0 kg/m². **B:** Meta-analysis plot comprising all 20,464 individuals stratified on 10-year age strata. Each age stratum reflects the age at baseline. No heterogeneity between the subgroups was detected ($P = 0.967$). Moderate heterogeneity was, however, observed in two of the subgroups.

and from then on the BMI difference between the genotypes becomes more or less constant throughout life. Nevertheless, it remains to be seen whether other relevant factors such as diet and physical activity may interact and modify the susceptibility to obesity by the *FTO* variants during the life course (37–39).

In summary, we have replicated that a common variant in the *FTO* gene alters type 2 diabetes risk but find that this association is partly independent of the effect on BMI. Our data further demonstrate that the weight gain as a result of the *FTO* risk variant occurs during youth and that the BMI difference according to the *FTO* genotype persists at the same level throughout life, setting the threshold for BMI.

ACKNOWLEDGMENTS

The HUNT study was supported in part by funds from the University of Bergen, Haukeland University Hospital, Helse Vest, Innovest, and the Research Council of Norway. Genotyping was in part provided by the CIGENE technology platform (Ås, Norway), which is supported by the Functional Genomics Programme (FUGE) of the Research Council of Norway. HUNT is a collaboration between the HUNT Research Center at the Norwegian University of Science and Technology, Levanger; the Norwegian Institute for Public Health; and the Nord-Trøndelag County Council. The diabetes part of HUNT was partly supported by funds from GlaxoSmithKline Norway and the Norwegian Diabetes

Association. The MDC study was supported by project grants from the Swedish Research Council, the European Foundation for the Study of Diabetes, the Novo Nordisk and Albert Pålsson Foundations, a Linnaeus grant to the Lund University Diabetes Centre, and the Knut and Alice Wallenberg Foundation. The MPP study was supported by grants from the Swedish Research Council (including Linné grant 31475113580), the Heart and Lung Foundation, the Diabetes Research Society, a Nordic Center of Excellence Grant in Disease Genetics, the Diabetes Program at the Lund University, the European Foundation for the Study of Diabetes, the Pålsson Foundation, the Craaford Foundation, the Novo Nordisk Foundation, the European Network of Genomic and Genetic Epidemiology, and the Wallenberg Foundation. L.G. has been a consultant for and served on advisory boards for sanofi-aventis, GlaxoSmithKline, Novartis, Merck, Tethys Bioscience, and Xoma and received lecture fees from Eli Lilly and Novartis. No other potential conflicts of interest relevant to this article were reported.

J.K.H. and S.J. designed the study, wrote the manuscript, researched data, contributed to the discussion, and reviewed and edited the manuscript. E.S. and A.J. researched data and reviewed and edited the manuscript. R.T.L. contributed to the discussion and reviewed and edited the manuscript. C.G.P.P. researched data and contributed to the discussion. P.M.N. contributed to the discussion and reviewed and edited the manuscript. G.R. researched data. K.M. researched data and reviewed and edited the manuscript. K.H. researched data, contributed to the discussion, and reviewed and edited the manuscript. O.M. reviewed and edited the manuscript. L.G. contributed to the discussion and reviewed and edited the manuscript. V.L. researched data and reviewed and edited the manuscript. A.M. designed the study, contributed to the discussion, and reviewed and edited the manuscript. M.O.-M. researched data and reviewed and edited the manuscript. P.R.N. designed the study, contributed to the discussion, and reviewed and edited the manuscript.

REFERENCES

- Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. *Nat Genet* 2007;39:724–726
- Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* 2007;316:889–894
- Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* 2007;316:1341–1345
- Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. *PLoS Genet* 2007;3:e115
- Fawcett KA, Barroso I. The genetics of obesity: FTO leads the way. *Trends Genet* 2010;26:266–274
- Al-Attar SA, Pollex RL, Ban MR, et al. Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. *Cardiovasc Diabetol* 2008;7:5
- Barber TM, Bennett AJ, Groves CJ, et al. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. *Diabetologia* 2008;51:1153–1158
- Freathy RM, Timpson NJ, Lawlor DA, et al. Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. *Diabetes* 2008;57:1419–1426
- Hertel JK, Johansson S, Raeder H, et al. Genetic analysis of recently identified type 2 diabetes loci in 1,638 unselected patients with type 2 diabetes and 1,858 control participants from a Norwegian population-based cohort (the HUNT study). *Diabetologia* 2008;51:971–977
- Hunt SC, Stone S, Xin Y, et al. Association of the FTO gene with BMI. *Obesity (Silver Spring)* 2008;16:902–904
- Jess T, Zimmermann E, Kring SI, et al. Impact on weight dynamics and general growth of the common FTO rs9939609: a longitudinal Danish cohort study. *Int J Obes (Lond)* 2008;32:1388–1394
- Marville AF, Lange LA, Qin L, Adair LS, Mohlke KL. Association of FTO with obesity-related traits in the Cebu Longitudinal Health and Nutrition Survey (CLHNS) Cohort. *Diabetes* 2008;57:1987–1991
- Qi L, Kang K, Zhang C, et al. Fat mass-and obesity-associated (FTO) gene variant is associated with obesity: longitudinal analyses in two cohort studies and functional test. *Diabetes* 2008;57:3145–3151
- Tabara Y, Osawa H, Guo H, et al. Prognostic significance of FTO genotype in the development of obesity in Japanese: the J-SHIP study. *Int J Obes (Lond)* 2009;33:1243–1248
- Wangensteen T, Egeland T, Akselsen H, Holmen J, Undlien D, Retterstol L. FTO Genotype and Weight Gain in Obese and Normal Weight Adults From a Norwegian Population Based Cohort (the HUNT Study). *Exp Clin Endocrinol Diabetes*, 2010;118:649–652
- Jacobsson JA, Riserus U, Axelsson T, Lannfelt L, Schiöth HB, Fredriksson R. The common FTO variant rs9939609 is not associated with BMI in a longitudinal study on a cohort of Swedish men born 1920–1924. *BMC Med Genet* 2009;10:131
- Luan J, Kerner B, Zhao JH, et al. A multilevel linear mixed model of the association between candidate genes and weight and body mass index using the Framingham longitudinal family data. *BMC Proc* 2009;3 (Suppl. 7):S115
- Kaakinen M, Läärä E, Pouta A, et al. Life-course analysis of a fat mass and obesity-associated (FTO) gene variant and body mass index in the Northern Finland Birth Cohort 1966 using structural equation modeling. *Am J Epidemiol* 2010;172:653–665
- Holmen J, Midtthell K, Krüger Ø, et al. The Nord-Trøndelag Health Study 1995–97 (HUNT2): objectives, contents, methods and participation. *Nor Epidemiol* 2003;13:19–32
- Berglund G, Elmståhl S, Janzon L, Larsson SA. The Malmö Diet and Cancer Study. Design and feasibility. *J Intern Med* 1993;233:45–51
- Nilsson P, Berglund G. Prevention of cardiovascular disease and diabetes: lessons from the Malmö Preventive Project. *J Intern Med* 2000;248:455–462
- Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;81:559–575
- Harris R, Bradburn M, Deeks J, et al. METAN: Stata module for fixed and random effects meta-analysis. In *Statistical Software Components S456798*. Chestnut Hill, MA, Boston College Department of Economics, Revised 19 May 2009
- Mägi R, Morris AP. GWAMA: software for genome-wide association meta-analysis. *BMC Bioinformatics* 2010;11:288
- Sanghera DK, Ortega L, Han S, et al. Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk. *BMC Med Genet* 2008;9:59
- Bressler J, Kao WH, Pankow JS, Boerwinkle E. Risk of type 2 diabetes and obesity is differentially associated with variation in FTO in whites and African-Americans in the ARIC study. *PLoS ONE* 2010;5:e10521
- Yajnik CS, Janipalli CS, Bhaskar S, et al. FTO gene variants are strongly associated with type 2 diabetes in South Asian Indians. *Diabetologia* 2009; 52:247–252
- Berulava T, Horsthemke B. The obesity-associated SNPs in intron 1 of the FTO gene affect primary transcript levels. *Eur J Hum Genet* 2010;18:1054–1056
- Zabena C, González-Sánchez JL, Martínez-Larrad MT, et al. The FTO obesity gene. Genotyping and gene expression analysis in morbidly obese patients. *Obes Surg* 2009;19:87–95
- Kirkpatrick CL, Marchetti P, Purrello F, et al. Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. *PLoS ONE* 2010;5:e11053
- Portisano NJ, Lew PS, Mizuno TM. Relationship between blood glucose levels and hepatic Fto mRNA expression in mice. *Biochem Biophys Res Commun* 2010;400:713–717
- Bravard A, Lefai E, Meunier E, et al. FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction. *Diabetes* 2011;60:258–268
- Ragvin A, Moro E, Fredman D, et al. Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHX4, SOX4, and IRX3. *Proc Natl Acad Sci USA* 2010;107:775–780
- López-Bermejo A, Petry CJ, Díaz M, et al. The association between the FTO gene and fat mass in humans develops by the postnatal age of two weeks. *J Clin Endocrinol Metab* 2008;93:1501–1505

35. Hakanen M, Raitakari OT, Lehtimäki T, et al. FTO genotype is associated with body mass index after the age of seven years but not with energy intake or leisure-time physical activity. *J Clin Endocrinol Metab* 2009;94:1281–1287
36. Rzehak P, Scherag A, Grallert H, et al; GINI and LISA Study Group. Associations between BMI and the FTO gene are age dependent: results from the GINI and LISA birth cohort studies up to age 6 years. *Obes Facts* 2010;3:173–180
37. Sonestedt E, Roos C, Gullberg B, Ericson U, Wirfält E, Orho-Melander M. Fat and carbohydrate intake modify the association between genetic variation in the FTO genotype and obesity. *Am J Clin Nutr* 2009;90:1418–1425
38. Vimalleswaran KS, Li S, Zhao JH, et al. Physical activity attenuates the body mass index-increasing influence of genetic variation in the FTO gene. *Am J Clin Nutr* 2009;90:425–428
39. Andreassen CH, Stender-Petersen KL, Mogensen MS, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. *Diabetes* 2008;57:95–101

SUPPLEMENTARY DATA

Supplementary Table 1. Association results between the *FTO* SNP rs9939609 and obesity-related quantitative traits in 5,596 individuals from the HUNT2 cohort.

Traits	<i>n</i>	Effect size*	SE	P-value [†]	P-value SNP - age interaction [‡]
BMI 1985 (baseline)	4625	0.218	0.083	0.008	0.209
BMI 1995 (follow-up)	5596	0.269	0.082	0.001	0.185
BMI 1985-95	4625	-0.019	0.051	0.716	0.889
Waist-hip ratio	5552	0.003	0.001	0.023	0.968
Waist circumference	5552	0.607	0.204	0.003	0.385
Hip circumference	5553	0.417	0.163	0.010	0.204

*All effect sizes represent the change in trait per risk allele.

[†]Age, gender and diabetes status were included as covariates in the regression models.

[‡]An additional SNP-age interaction term was introduced in the regression model to detect whether age modifies the associations.

Supplementary Table 2. Association results between the *FTO* SNP rs939609 and serum lipid measures in the HUNT2, MPP and MDC cohorts individually, and in the HUNT2-MPP-MDC combined analysis. A) Linear regression models corrected for age, gender and diabetes status. B) Linear regression models corrected for age, gender, diabetes status and BMI.

		HUNT2				MPP				MDC				Combined			
Traits	N	Effect size	SE	P-value	N	Effect size	SE	P-value	N	Effect size	SE	P-value	N	Effect size	95% CI	P-value	
A)																	
Triglycerides	5583	0.037	0.010	2.0×10^{-4}	15823	-0.002	0.005	0.73	3228	0.013	0.021	0.30	24634	0.006	-0.002, 0.015	0.16	
Cholesterol	5584	0.003	0.004	0.48	15834	-0.003	0.002	0.11	3229	-0.004	0.028	0.99	24647	-0.002	-0.005, 0.002	0.31	
HDL-C	5582	-0.017	0.005	2.0×10^{-3}	15824	-0.003	0.003	0.39	3188	-0.002	0.009	0.73	24594	-0.006	-0.011, -0.002	0.01	
B)																	
Triglycerides	5583	0.027	0.009	5.0×10^{-3}	15823	-0.010	0.005	0.10	3228	-0.010	0.021	0.77	24634	-0.002	-0.010, 0.007	0.70	
Cholesterol	5584	0.001	0.004	0.75	15834	0.000	0.002	0.17	3229	-0.015	0.028	0.71	24647	0.000	-0.003, 0.004	0.94	
HDL-C	5582	-0.013	0.005	0.02	15824	0.000	0.003	0.73	3188	0.009	0.009	0.34	24594	-0.003	-0.007, 0.002	0.31	


All serum lipids data were log transformed (natural) for normality.

All effect sizes represent the change in trait per risk allele.

The estimates of the combined effects were calculated using a fixed-effect model with inverse variance.


SUPPLEMENTARY DATA

Supplementary Figure 1. Scatter-plots showing the individual BMI values by age and *FTO* rs9939609 genotype for the HUNT2 subjects. The corresponding fitted curves are estimated by the locally weighted least squares method (LOWESS). Red, blue and green dots and smoothed curves represent those subjects homozygote for the risk allele, heterozygote and those without the risk allele, respectively. Note that the scatter-plots at the right are truncated and only contain BMI values between 20-35 kg/m². The Lowess regression curves, however, are based on the whole range of BMI values (14.7 - 51.7 kg/m²) shown to the left. Panel A, B and C are scatter-plots with smoothed curves for BMI by age and genotype for all subjects combined, individuals without diabetes and for those with type 2 diabetes, respectively.




SUPPLEMENTARY DATA


Supplementary Figure 2. Meta-analysis plots of association between *FTO* and type 2 diabetes, comprising 4,317 subjects with type 2 diabetes and 37,187 control subjects. Panel A: Meta-analysis plot of association between *FTO* rs9939609 and type 2 diabetes after correction for age and gender (allelic OR 1.13, 95% CI 1.08–1.19). Panel B: Meta-analysis plot of association between *FTO* rs9939609 and type 2 diabetes after correction for age, gender and waist-to-hip ratio (allelic OR 1.12, 95% CI 1.07–1.17). Panel C: Meta-analysis plot of association between *FTO* rs9939609 and type 2 diabetes after correction for age, gender and waist circumference (allelic OR 1.11, 95% CI 1.06–1.16). We observed a tendency towards heterogeneity between the samples ($P = 0.04$ – 0.09) in the meta-analyses, and the variation in the estimates attributable to heterogeneity was calculated to 63.7%, 58.2% and 69.3% for panel A, B and C, respectively. The ORs for the overall estimates were calculated using a fixed-effect model with inverse variance. The weighting (% weight) represents the inverse variance of each studies' effect estimator.



SUPPLEMENTARY DATA




Supplementary Figure 3. Meta-analysis plots of association between *FTO* and risk to develop incident type 2 diabetes, comprising 3,143 subjects with incident type 2 diabetes during follow-up and 16,092 control subjects from the HUNT and MPP cohorts. Panel A: Meta-analysis plot of association between *FTO* rs9939609 and incident type 2 diabetes after correction for gender and baseline age (allelic OR 1.16, 95% CI 1.10-1.22, $P=3.2 \times 10^{-8}$). Panel B: Meta-analysis plot of association between *FTO* rs9939609 and type 2 diabetes after correction for gender and baseline age and BMI (allelic OR 1.12, 95% CI 1.05-1.18, $P=1.1 \times 10^{-4}$). Panel C: Meta-analysis plot of association between *FTO* rs9939609 and incident type 2 diabetes after correction for gender, baseline age and BMI and delta of BMI (allelic OR 1.11, 95% CI 1.05-1.18, $P=1.5 \times 10^{-4}$). The ORs for the overall estimates were calculated using a fixed-effect model with inverse variance. The weighting (% weight) represents the inverse variance of each studies' effect estimator.



SUPPLEMENTARY DATA

B



C

